Linagliptin Found Effective, Safe in African Americans With Type 2 Diabetes
Clinical Trials Tuesday, May 29th, 2012Cardiology News Digital Network: By: MIRIAM E. TUCKER, 5/25/2012.
PHILADELPHIA – Linagliptin was associated with significant improvements in hyperglycemia in a multicenter, randomized, placebo-controlled, double-blind trial of 226 African-American patients with type 2 diabetes.
“African Americans have a 77% greater likelihood of developing diabetes yet tend to be underrepresented in clinical trials of antidiabetic drugs,” said Dr. James R. Thrasher, director of medical investigation at Arkansas Diabetes and Endocrinology Center, Little Rock. “We wanted to look at this group with higher rates of diabetes and higher risk for complications of diabetes.” Read more